CR20190113A - Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma - Google Patents
Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la mismaInfo
- Publication number
- CR20190113A CR20190113A CR20190113A CR20190113A CR20190113A CR 20190113 A CR20190113 A CR 20190113A CR 20190113 A CR20190113 A CR 20190113A CR 20190113 A CR20190113 A CR 20190113A CR 20190113 A CR20190113 A CR 20190113A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutically acceptable
- synthesis
- acceptable salts
- invención
- compuesto
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- ASROSKVBCYFAHU-IONNQARKSA-N (2s)-2-amino-4-methyl-1-[(2r)-2-methyloxiran-2-yl]pentan-1-one Chemical compound CC(C)C[C@H](N)C(=O)[C@@]1(C)CO1 ASROSKVBCYFAHU-IONNQARKSA-N 0.000 title 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 abstract 2
- 229960002438 carfilzomib Drugs 0.000 abstract 2
- 108010021331 carfilzomib Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 1
- 238000006735 epoxidation reaction Methods 0.000 abstract 1
- 229910052748 manganese Inorganic materials 0.000 abstract 1
- 239000011572 manganese Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/1616—Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/02—Synthesis of the oxirane ring
- C07D301/03—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
- C07D301/12—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with hydrogen peroxide or inorganic peroxides or peracids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/70—Complexes comprising metals of Group VII (VIIB) as the central metal
- B01J2531/72—Manganese
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epoxy Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371686P | 2016-08-05 | 2016-08-05 | |
| US201762536862P | 2017-07-25 | 2017-07-25 | |
| PCT/US2017/045274 WO2018027021A1 (en) | 2016-08-05 | 2017-08-03 | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190113A true CR20190113A (es) | 2019-04-25 |
Family
ID=59593230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190113A CR20190113A (es) | 2016-08-05 | 2017-08-03 | Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11708341B2 (es) |
| EP (1) | EP3494108B1 (es) |
| JP (1) | JP7229912B2 (es) |
| KR (1) | KR102482663B1 (es) |
| CN (1) | CN109641863B (es) |
| AU (1) | AU2017306546B2 (es) |
| CL (1) | CL2019000294A1 (es) |
| CO (1) | CO2019001139A2 (es) |
| CR (1) | CR20190113A (es) |
| CY (1) | CY1124363T1 (es) |
| DK (1) | DK3494108T3 (es) |
| ES (1) | ES2842575T3 (es) |
| HU (1) | HUE051980T2 (es) |
| IL (1) | IL264549B (es) |
| JO (1) | JOP20190016B1 (es) |
| LT (1) | LT3494108T (es) |
| MX (1) | MX383751B (es) |
| MY (1) | MY204928A (es) |
| PE (1) | PE20190404A1 (es) |
| PH (1) | PH12019500232B1 (es) |
| PL (1) | PL3494108T3 (es) |
| PT (1) | PT3494108T (es) |
| SA (1) | SA519401022B1 (es) |
| SG (2) | SG10201912268UA (es) |
| SI (1) | SI3494108T1 (es) |
| TN (1) | TN2019000028A1 (es) |
| UA (1) | UA125648C2 (es) |
| WO (1) | WO2018027021A1 (es) |
| ZA (1) | ZA201900717B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114195741A (zh) * | 2021-12-28 | 2022-03-18 | 南京格亚医药科技有限公司 | 一种卡非佐米关键中间体异构体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| AU2005243140A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| JP2006028154A (ja) | 2004-06-14 | 2006-02-02 | Sumitomo Chemical Co Ltd | 光学活性化合物の製造方法 |
| PT2260835E (pt) | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
| KR20170125413A (ko) | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| EP3090737A1 (en) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| MY196510A (en) | 2012-05-08 | 2023-04-18 | Onyx Therapeutics Inc | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| EP2874605A1 (en) | 2012-07-18 | 2015-05-27 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| DE102013104003B3 (de) | 2013-04-19 | 2014-03-13 | Glatt Systemtechnik Gmbh | Vorrichtung zum Einbringen einer definierten Menge eines zweiten Pulvers in einen Prozessbehälter |
| CN104230857A (zh) | 2014-08-19 | 2014-12-24 | 上海皓元生物医药科技有限公司 | 卡非佐米(Carfilzomib)的中间体化合物的制备方法及其中间体化合物 |
-
2017
- 2017-08-03 ES ES17751954T patent/ES2842575T3/es active Active
- 2017-08-03 CR CR20190113A patent/CR20190113A/es unknown
- 2017-08-03 LT LTEP17751954.3T patent/LT3494108T/lt unknown
- 2017-08-03 JP JP2019506144A patent/JP7229912B2/ja active Active
- 2017-08-03 HU HUE17751954A patent/HUE051980T2/hu unknown
- 2017-08-03 PE PE2019000337A patent/PE20190404A1/es unknown
- 2017-08-03 PL PL17751954T patent/PL3494108T3/pl unknown
- 2017-08-03 PT PT177519543T patent/PT3494108T/pt unknown
- 2017-08-03 EP EP17751954.3A patent/EP3494108B1/en active Active
- 2017-08-03 CN CN201780048527.3A patent/CN109641863B/zh active Active
- 2017-08-03 WO PCT/US2017/045274 patent/WO2018027021A1/en not_active Ceased
- 2017-08-03 UA UAA201902137A patent/UA125648C2/uk unknown
- 2017-08-03 KR KR1020197006357A patent/KR102482663B1/ko active Active
- 2017-08-03 SG SG10201912268UA patent/SG10201912268UA/en unknown
- 2017-08-03 SG SG11201900991UA patent/SG11201900991UA/en unknown
- 2017-08-03 MX MX2019001459A patent/MX383751B/es unknown
- 2017-08-03 US US16/327,079 patent/US11708341B2/en active Active
- 2017-08-03 MY MYPI2019000529A patent/MY204928A/en unknown
- 2017-08-03 JO JOP/2019/0016A patent/JOP20190016B1/ar active
- 2017-08-03 PH PH1/2019/500232A patent/PH12019500232B1/en unknown
- 2017-08-03 DK DK17751954.3T patent/DK3494108T3/da active
- 2017-08-03 AU AU2017306546A patent/AU2017306546B2/en active Active
- 2017-08-03 SI SI201730575T patent/SI3494108T1/sl unknown
- 2017-08-03 TN TNP/2019/000028A patent/TN2019000028A1/en unknown
-
2019
- 2019-01-30 IL IL264549A patent/IL264549B/en unknown
- 2019-02-04 CL CL2019000294A patent/CL2019000294A1/es unknown
- 2019-02-04 ZA ZA2019/00717A patent/ZA201900717B/en unknown
- 2019-02-04 SA SA519401022A patent/SA519401022B1/ar unknown
- 2019-02-07 CO CONC2019/0001139A patent/CO2019001139A2/es unknown
-
2021
- 2021-01-27 CY CY20211100067T patent/CY1124363T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124789T1 (el) | Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| CO2022002637A2 (es) | Proceso de fabricación de moduladores de cftr | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| DOP2018000275A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| MX2018011139A (es) | Acido acrilico y metodos para producir el mismo. | |
| CR20160538A (es) | Combinación | |
| AR102767A1 (es) | Inhibidores de ezh2 | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| MX370611B (es) | Metodos utiles en la sintesis de analogos de halicondrina b. | |
| MX2024009894A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| MX2018014176A (es) | Capsulas que comprenden bencilpropargileteres para usar como inhibidores de la nitrificacion. | |
| MA43650B1 (fr) | Formulations/compositions comprenant un inhibiteur de btk | |
| MX2017007551A (es) | Derivado de dihidroindolizinona. | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| CY1121147T1 (el) | Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου | |
| MX2018007721A (es) | Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal. | |
| MX2019002065A (es) | Derivado de triazolopirazinona util como un inhibidor de pde1 humana. | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| DOP2016000293A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| MX380172B (es) | Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. | |
| CR20190113A (es) | Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma | |
| MX390841B (es) | Preparacion liquida parenteral que comprende compuesto de carbamato. |